SHERIDAN, WYOMING -- July 10, 2026 -- Biogena founder and CEO Dr. Albert Schmidbauer outlined the strategic rationale behind his company's planned stock market listing in a recent podcast interview, positioning preventive health as a major European growth sector. The Salzburg-based micronutrient and preventive health company aims to raise up to 25 million euros through its listing on the Vienna Stock Exchange Direct Market Plus. Schmidbauer discussed the company's evolution from a niche market pioneer to an international health brand serving approximately one million customers across 70 countries.
Biogena Targets 25 Million Euro Capital Raise Through Vienna Listing
The planned stock offering will value Biogena at approximately 450 million euros. Schmidbauer explained the dual purpose of the capital market strategy in the DUP Business Talk podcast hosted by Jens de Buhr. Beyond raising growth capital, the company intends to involve its customer community directly in the business development. The listing represents a strategic shift for a company that reported revenue of 124.9 million euros and EBITDA of 19.1 million euros for fiscal year 2024/25.
Schmidbauer framed the offering as more than a financial transaction. He described it as building a community united by a shared belief in health as a future-oriented investment category. The approach connects two perspectives rarely considered together: personal health investment and financial investment in companies benefiting from the preventive health trend.
Prevention Over Treatment Drives Business Model
The Biogena founder traced his company's origins to a fundamental question about healthcare system priorities. Rather than waiting for illness to occur, Schmidbauer focused on understanding what the body requires to maintain health and performance. This prevention-first philosophy has shaped product development and market positioning since the company's 2006 founding.
The business model centers on micronutrient supplements combined with diagnostic services, prevention programs, and longevity-focused offerings. Schmidbauer argued that healthcare systems must shift resources toward prevention rather than concentrating exclusively on disease treatment. This operational approach differentiates Biogena in a market where reactive medical intervention remains the dominant model.
Health Positioned as Financial and Personal Asset Class
Schmidbauer introduced the concept of health as life capital during the podcast discussion. He suggested that health will increasingly be understood as a wealth component beyond its financial implications. This framing connects individual wellness decisions with broader economic trends in the preventive health sector. The perspective aligns with Biogena's strategy of engaging customers as both product users and potential shareholders.
The CEO emphasized that the capital raise serves growth objectives while creating stakeholder alignment. By offering shares to customers who already use Biogena products, the company builds a shareholder base with direct experience of its offerings. This community-focused approach to capital markets reflects the company's positioning at the intersection of personal health management and investment strategy.
International Expansion Supports Revenue Growth
Biogena operates across 70 countries with a customer base approaching one million users. The company develops micronutrient formulations and provides diagnostic services designed to support preventive health strategies. Revenue growth has positioned the business as one of the leading European providers in its category, though specific market share data was not disclosed.
The planned capital injection will fund continued international expansion. Schmidbauer discussed the operational challenges of building trust in health markets, identifying it as a critical success factor. Product quality and customer confidence drive repeat business in a sector where purchasing decisions involve personal health outcomes.
Founder Discusses Entrepreneurial Persistence and Strategy
During the podcast, Schmidbauer addressed business setbacks and the importance of persistence in building a health brand. He described his decision to avoid developing a backup plan, committing fully to the preventive health concept even when the market showed limited initial interest. The founder cited Arnold Schwarzenegger as an influence, focusing on the discipline and goal orientation demonstrated throughout Schwarzenegger's business career rather than his celebrity status.
Trust emerged as a recurring theme in the discussion. Schmidbauer explained that customer confidence in product quality and company integrity determines long-term success in health markets. This focus on relationship building has shaped Biogena's approach to customer engagement and community development.
Preventive Health Sector Gains Economic Momentum
Podcast host Jens de Buhr positioned the conversation within a broader market shift. Health is transitioning from an individual lifestyle concern to an economic growth sector with implications for entrepreneurship, capital markets, and social policy. The preventive health category benefits from demographic trends and increasing consumer focus on wellness and longevity.
Biogena's business performance illustrates this market evolution. The company's revenue and profitability growth demonstrate commercial viability for prevention-focused health businesses. The planned stock listing will test investor appetite for companies operating in this category and may influence how capital markets value preventive health enterprises.
The DUP Business Talk podcast featuring Dr. Albert Schmidbauer is available on major podcast platforms and YouTube. Additional information about Biogena and the planned stock offering can be found at https://www.biogena.com